Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stratified Therapy on Pediatric AAGN Based on Risk Assessment
NCT05969522Phase 4Recruiting
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab, cyclophosphamide in ANCA-associated glomerulonephritis (ANCA-GN). Started Jan 2023; status: recruiting.
02
Drugs
rituximabcyclophosphamide
03
Conditions
ANCA-associated glomerulonephritis (ANCA-GN)
Beyond the preview
Go deeper on NCT05969522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05969522.